Key result
IFN-beta1b in primary progressive MS is linked to higher IL-10 and modulated PBMC cytokine patterns.
Why the study?
It is unknown whether the immunological effects of beta-interferon differ in primary progressive multiple sclerosis compared with relapsing-remitting multiple sclerosis.
Does interferon-beta1b treatment modulate cytokines in patients with primary progressive multiple sclerosis?
Does interferon-beta1b treatment modulate cytokines in patients with primary progressive multiple sclerosis?
p-value: p=0.02
Interferon-beta1b treatment in primary progressive multiple sclerosis alters cytokine patterns differently than in relapsing-remitting multiple sclerosis, suggesting distinct immunological mechanisms.
Supports distinct cytokine modulation by IFN-beta1b in PPMS; leaves open clinical relevance pending randomized trials.
OBJECTIVES: It is unknown whether the immunological effects of beta-interferon (IFN-beta) differ in primary progressive multiple sclerosis (PPMS) when compared with relapsing-remitting multiple sclerosis (RRMS). Therefore, we investigated the effects of IFN-beta1b treatment in PPMS on proliferation and cytokine pattern of peripheral blood mononuclear cells (PBMC) and interleukin-10 (IL-10) serum level. METHODS: Eighteen patients were treated with IFN-beta1b for 12 months in an open-label trial. Serum and PBMC were collected longitudinally. RESULTS: Interleukin-10 serum levels increased (P = 0.02) during treatment. Tumor necrosis factor-alpha was increased in anti CD3 (OKT3) antibody stimulated PBMC during treatment (P = 0.04), whereas secretion of IL-10 was decreased in OKT3 (P = 0.04), but increased in concavalin A stimulated PBMC (P = 0.02). CONCLUSIONS: Interleukin-10 serum levels rose in IFN-beta1b-treated patients as has been observed in RRMS. The changes in cytokine patterns secreted by T-lymphocytes of PPMS patients, however, differ from effects observed in RRMS supporting the hypothesis that PPMS differs in some immunological aspects from RRMS.
No takes yet. Share an insight, caveat, or question.
Dressel et al. (2006) studied Primary progressive multiple sclerosis (n=18). IFN-beta1b was evaluated on Interleukin-10 (IL-10) serum level and cytokine pattern of peripheral blood mononuclear cells (PBMC) (p=0.02). IFN-beta1b treatment in patients with primary progressive multiple sclerosis significantly increased interleukin-10 serum levels (P=0.02) and modulated PBMC cytokine patterns.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: